5,122 Johnson & Johnson $JNJ Shares Sold by Perpetual Ltd

Key Points

• Perpetual Ltd cut its Johnson & Johnson position by 21.4%, selling 5,122 shares and retaining 18,795 shares valued at approximately $4.98 million. Institutional investors own 69.55% of JNJ.
• Johnson & Johnson’s third-quarter adjusted EPS of $2.59 topped estimates, while revenue rose 5.9% to $25.4 billion; the company also raised its FY 2026 adjusted EPS guidance to $11.05–$11.15.
• Despite the earnings beat, shares opened down 5.6% at $248.90 amid MedTech weakness and substantial charges that drove reported profit sharply lower. Analysts maintain a “Moderate Buy” consensus with a $276.22 price target, and JNJ declared a $1.34 quarterly dividend.

Perpetual Ltd lowered its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 21.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,795 shares of the company's stock after selling 5,122 shares during the quarter. Perpetual Ltd's holdings in Johnson & Johnson were worth $4,976,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Vertrix Wealth Management LLC lifted its holdings in Johnson & Johnson by 1.5% in the 3rd quarter. Vertrix Wealth Management LLC now owns 14,714 shares of the company's stock worth $3,895,000 after purchasing an additional 222 shares in the last quarter. Sacks & Associates LLC purchased a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $279,000. Roan Capital Partners grew its holdings in Johnson & Johnson by 49.1% during the 3rd quarter. Roan Capital Partners now owns 1,281 shares of the company's stock valued at $339,000 after buying an additional 422 shares in the last quarter. Arbor Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $207,000. Finally, Armstrong Advisory Group Inc. raised its position in shares of Johnson & Johnson by 6.3% during the third quarter. Armstrong Advisory Group Inc. now owns 5,742 shares of the company's stock valued at $1,520,000 after buying an additional 342 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on JNJ. Argus set a $300.00 target price on shares of Johnson & Johnson in a research report on Wednesday, July 29th. Johnson Rice reiterated a "buy" rating on shares of Johnson & Johnson in a report on Monday, August 3rd. The Goldman Sachs Group reiterated a "buy" rating and issued a $282.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, Weiss Ratings raised shares of Johnson & Johnson from a "buy (b)" rating to a "buy (b+)" rating in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $276.22.

Insiders Place Their Bets

In related news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 87,569 shares of company stock worth $23,064,544 in the last three months. Insiders own 0.16% of the company's stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ reported third-quarter adjusted EPS of $2.59, exceeding the $2.53 consensus estimate, while revenue rose 5.9% year over year to approximately $25.4 billion. Johnson & Johnson Q3 earnings report
• Positive Sentiment: The company raised its FY 2026 outlook to adjusted EPS of $11.05–$11.15 and revenue of $101.0–$101.4 billion. The EPS midpoint is broadly in line with consensus, while the revenue midpoint is slightly below the $101.3 billion estimate. Johnson & Johnson reports Q3 2026 results
• Positive Sentiment: Innovative Medicine led the quarter, with oncology growth of 17%, renewed immunology growth despite Stelara exclusivity losses, and continued momentum from TREMFYA. New long-term Crohn’s disease data could support the drug’s future commercial potential. TREMFYA Crohn’s disease data
• Neutral Sentiment: JNJ declared a quarterly dividend of $1.34 per share, or $5.36 annualized, supporting its income-investment appeal. The payment is scheduled for December 8 to shareholders of record on November 24. Johnson & Johnson quarterly dividend announcement
• Negative Sentiment: MedTech grew operationally by about 2.5% but missed expectations, with weakness in cardiovascular and surgery businesses outside the United States. Management said the segment needs to improve, intensifying concerns about the division’s near-term growth prospects.
• Negative Sentiment: Reported third-quarter profit fell sharply to roughly $210 million, or $0.09 per share, because of charges related to the proposed talc litigation resolution, the Firefly Bio acquisition, and the Sail Biomedicines collaboration. These items overshadowed the adjusted earnings beat. Johnson & Johnson quarterly report analysis

Johnson & Johnson Stock Down 5.6%

Shares of NYSE:JNJ opened at $248.90 on Wednesday. The business's 50 day moving average is $265.89 and its 200 day moving average is $249.37. The stock has a market cap of $599.83 billion, a P/E ratio of 28.84, a price-to-earnings-growth ratio of 2.70 and a beta of 0.21. Johnson & Johnson has a 52-week low of $184.66 and a 52-week high of $281.07. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The business's revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts predict that Johnson & Johnson will post 11.09 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. Johnson & Johnson's dividend payout ratio (DPR) is 62.11%.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.